MGFA has partnered with Bionews to feature the “Myasthenia Gravis News” feed on our MGFA website. We are excited to offer the MG Community this insightful and informative news feed that covers many aspects of living with myasthenia – from research and study results to managing MG, helpful tips, and important news from across the MG World.
Myasthenia Gravis News is a digital platform intended to provide the myasthenia gravis (MG) community with the most recent news and information on MG, as well as first-hand community perspectives from patient and caregiver columnists. All articles on Myasthenia Gravis News are original content produced by in-house writers and editors. Occasionally, BioNews seeks the opinion of outside experts for interviews and Q&As.
Myasthenia Gravis News – The Web’s Daily Resource for Myasthenia Gravis News
- How I build a career with a body that has limits due to MG
by Sarah Bendiff on February 12, 2026 at 3:00 pmI love working. I love creating. I love staying active and leaving my mark on the world. But myasthenia gravis (MG) doesn’t always enjoy accompanying me on that path, so I had to come up with a plan to keep going. The struggles are real and concrete. One of the most frustrating symptoms that affected The post How I build a career with a body that has limits due to MG appeared first on Myasthenia Gravis News.
- Standard treatments help many people with rare double-seronegative MG
by Marisa Wexler, MS on February 12, 2026 at 1:00 pmStandard treatments helped many people with myasthenia gravis (MG) who lack the most common disease-causing antibodies, according to a new review study. The findings shed new light on how so-called double-seronegative MG (dSNMG) compares with more common forms of the disease and highlight the need for careful monitoring, particularly in cancer patients receiving newer immune-based The post Standard treatments help many people with rare double-seronegative MG appeared first on Myasthenia Gravis News.
- Arthritis drug tofacitinib may be effective for hard-to-treat MG: Study
by Michela Luciano, PhD on February 11, 2026 at 4:00 pmTofacitinib, an approved medication for some types of inflammatory arthritis and inflammatory bowel disease, improves muscle strength, daily functioning, and quality of life in people with hard-to-treat myasthenia gravis (MG), according to a small pilot clinical trial. Slightly more than half of the participants experienced few or no symptoms after six months of tofacitinib, which The post Arthritis drug tofacitinib may be effective for hard-to-treat MG: Study appeared first on Myasthenia Gravis News.
- New MG app helps doctors track symptoms between clinic visits
by Steve Bryson, PhD on February 10, 2026 at 1:00 pmA new digital platform — MyaLink — enables doctors to monitor the physical and mental health of people with myasthenia gravis (MG) in real time and communicate directly with patients through the app, a study shows. Data collected by MyaLink on MG patients’ symptoms, disease activity, daily functioning, and quality of life captured wide day-to-day The post New MG app helps doctors track symptoms between clinic visits appeared first on Myasthenia Gravis News.
- How to make room for intimacy when chronic illness enters a relationship
by Shawna Barnes on February 9, 2026 at 3:00 pmIntimacy becomes a different kind of conversation when a chronic illness like myasthenia gravis (MG) enters a relationship. Before my diagnosis, I believed closeness was mostly about desire, timing, and connection. I didn’t realize how much it also depended on muscle strength, breath control, and the ability to stay present in my own body. When The post How to make room for intimacy when chronic illness enters a relationship appeared first on Myasthenia Gravis News.
** MGFA Disclaimer – Please read
Myasthenia Gravis Foundation of America (MGFA) and Bionews, Inc. (specifically Myasthenia Gravis News) have entered into a limited agreement that allows for the MGFA to post a link to Myasthenia Gravis News on the myasthenia.org website. Myasthenia Gravis News is a digital platform intended to provide the myasthenia gravis (MG) community with the most recent news and information on MG, as well as first-hand community perspectives from patient and caregiver columnists. All articles on Myasthenia Gravis News are original content produced by in-house writers and editors. Occasionally, Bionews seeks the opinion of outside experts for interviews and Q&As.
The publishing team at Myasthenia Gravis News is made up of science writers and editors, most of whom have PhDs in the life sciences; veteran journalists; and columnists who are members of the MG community. Together, they attempt to ensure that all content published on Myasthenia Gravis News is relevant, accurate, informative, relatable, and easy to understand.
Each piece of content is carefully selected and written by Bionews writers with the MG community in mind. Sources for news stories and resource pages include peer-reviewed studies, press releases, announcements, interviews, webinars, and conference sessions, among others. All articles go through a stringent fact-checking and editing procedure as part of Bionews’ process to ensure they are accurate, objective, comprehensive, and well-explained.
Columns are written by MG patients and caregivers who provide an intimate look at what it’s like to live with the disease. While columns are largely opinion and perspective pieces, each one still goes through a comprehensive editing and fact-checking process by Bionews editors to ensure clarity, accuracy, and fairness.
Myasthenia Gravis News’ site is strictly a news and information website about the disease. It DOES NOT provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The information provided is for educational purposes only and does not substitute for professional medical advice.
The content reflects the unique experiences of the authors and is not necessarily the opinion, views, or recommendations of the MGFA. Medical advisors and clinicians associated with or partnering with the MGFA do not peer review articles and information posted on the Myasthenia Gravis News platform or website. MGFA should not be liable for any information, opinions, articles, advice, guidance, or details posted on the Myasthenia Gravis News site. MGFA has posted this platform as a service to the MG community. Please consult with your doctor and healthcare professionals for specific recommendations and advice pertaining to your healthcare/treatment.